QC
PRCT icon

Quadrature Capital’s Procept Biorobotics PRCT Stock Holding History

Quadrature Capital’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,389
Closed -$232K – 1749
2025
Q4 		$232K Buy
+7,389
New +$245K ﹤0.01% 930
2025
Q2 		– Sell
-14,723
Closed -$858K – 1387
2025
Q1 		$858K Buy
+14,723
New +$1.01M 0.02% 463

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Quadrature Capital's PRCT Position: Q1 2026 in Review

Quadrature Capital sold out of Procept Biorobotics (PRCT) in Q1 2026, closing a stake of 7,389 shares — an estimated $232K sold.

Quadrature Capital first reported a position in PRCT in Q1 2025 and held it in 2 quarters. The position peaked at $858K in Q1 2025. 257 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

  • Quadrature Capital reported no remaining Procept Biorobotics position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 7,389 Procept Biorobotics shares in Q1 2026, an estimated $232K.
  • Quadrature Capital first reported a position in Procept Biorobotics in Q1 2025 and held it in 2 quarters.
  • Quadrature Capital's Procept Biorobotics position peaked at $858K in Q1 2025.
  • 257 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.